These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Effect of Biannual Mass Azithromycin Distributions to Preschool-Aged Children on Trachoma Prevalence in Niger: A Cluster Randomized Clinical Trial. Arzika AM; Mindo-Panusis D; Abdou A; Kadri B; Nassirou B; Maliki R; Alsoudi AF; Zhang T; Cotter SY; Lebas E; O'Brien KS; Callahan EK; Bailey RL; West SK; Goodhew EB; Martin DL; Arnold BF; Porco TC; Lietman TM; Keenan JD; JAMA Netw Open; 2022 Aug; 5(8):e2228244. PubMed ID: 35997979 [TBL] [Abstract][Full Text] [Related]
24. Pharmacodynamic activity of azithromycin against macrolide-susceptible and -resistant Streptococcus pneumoniae simulating clinically achievable free serum, epithelial lining fluid and middle ear fluid concentrations. Zhanel GG; DeCorby M; Noreddin A; Mendoza C; Cumming A; Nichol K; Wierzbowski A; Hoban DJ J Antimicrob Chemother; 2003 Jul; 52(1):83-8. PubMed ID: 12775677 [TBL] [Abstract][Full Text] [Related]
25. Mass distribution of azithromycin for trachoma control is associated with increased risk of azithromycin-resistant Streptococcus pneumoniae carriage in young children 6 months after treatment. Coles CL; Mabula K; Seidman JC; Levens J; Mkocha H; Munoz B; Mfinanga SG; West S Clin Infect Dis; 2013 Jun; 56(11):1519-26. PubMed ID: 23487375 [TBL] [Abstract][Full Text] [Related]
31. Assessment of Long-Term Macrolide Exposure on the Oropharyngeal Microbiome and Macrolide Resistance in Healthy Adults and Consequences for Onward Transmission of Resistance. Burr LD; Taylor SL; Richard A; Schreiber V; Lingman S; Martin M; Papanicolas LE; Choo JM; Rogers GB Antimicrob Agents Chemother; 2022 Apr; 66(4):e0224621. PubMed ID: 35293783 [TBL] [Abstract][Full Text] [Related]
32. Community treatment with azithromycin for trachoma is not associated with antibiotic resistance in Streptococcus pneumoniae at 1 year. Gaynor BD; Holbrook KA; Whitcher JP; Holm SO; Jha HC; Chaudhary JS; Bhatta RC; Lietman T Br J Ophthalmol; 2003 Feb; 87(2):147-8. PubMed ID: 12543738 [TBL] [Abstract][Full Text] [Related]
34. Increased carriage of macrolide-resistant fecal E. coli following mass distribution of azithromycin for trachoma control. Seidman JC; Coles CL; Silbergeld EK; Levens J; Mkocha H; Johnson LB; Muñoz B; West SK Int J Epidemiol; 2014 Aug; 43(4):1105-13. PubMed ID: 24659584 [TBL] [Abstract][Full Text] [Related]
35. Long-term, low-dose azithromycin treatment reduces the incidence but increases macrolide resistance in Staphylococcus aureus in Danish CF patients. Hansen CR; Pressler T; Hoiby N; Johansen HK J Cyst Fibros; 2009 Jan; 8(1):58-62. PubMed ID: 18849202 [TBL] [Abstract][Full Text] [Related]
36. Baseline azithromycin resistance in the gut microbiota of preterm born infants. Gallacher DJ; Zhang L; Aboklaish AF; Mitchell E; Wach R; Marchesi JR; Kotecha S Pediatr Res; 2024 Jan; 95(1):205-212. PubMed ID: 37550487 [TBL] [Abstract][Full Text] [Related]
37. Biannual azithromycin distribution and child mortality among malnourished children: A subgroup analysis of the MORDOR cluster-randomized trial in Niger. O'Brien KS; Arzika AM; Maliki R; Manzo F; Mamkara AK; Lebas E; Cook C; Bailey RL; West SK; Oldenburg CE; Porco TC; Arnold B; Keenan JD; Lietman TM; PLoS Med; 2020 Sep; 17(9):e1003285. PubMed ID: 32931496 [TBL] [Abstract][Full Text] [Related]
38. Childhood Mortality After Mass Distribution of Azithromycin: A Secondary Analysis of the PRET Cluster-randomized Trial in Niger. O'Brien KS; Cotter SY; Amza A; Kadri B; Nassirou B; Stoller NE; Zhou Z; West SK; Bailey RL; Keenan JD; Porco TC; Lietman TM Pediatr Infect Dis J; 2018 Nov; 37(11):1082-1086. PubMed ID: 29561511 [TBL] [Abstract][Full Text] [Related]
39. Macrolide resistance determinants among Streptococcus pneumoniae isolates from carriers in Central Greece. Grivea IN; Sourla A; Ntokou E; Chryssanthopoulou DC; Tsantouli AG; Syrogiannopoulos GA BMC Infect Dis; 2012 Oct; 12():255. PubMed ID: 23057516 [TBL] [Abstract][Full Text] [Related]
40. Azithromycin treatment failure in community-acquired pneumonia caused by Streptococcus pneumoniae resistant to macrolides by a 23S rRNA mutation. Kays MB; Wack MF; Smith DW; Denys GA Diagn Microbiol Infect Dis; 2002 Jun; 43(2):163-5. PubMed ID: 12088625 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]